KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals (NASDAQ: KALV) has announced new inducement grants for recently hired employees. On January 2, 2025, nine new employees were granted options to purchase a total of 61,000 shares of KalVista common stock. Additionally, on January 6, 2025, one new employee received options to purchase 50,000 shares.
The options' exercise price equals the closing price of KalVista stock on their respective grant dates. The vesting schedule includes 25% after one year, with the remaining portions vesting monthly over three years, contingent on continued employment. All options have a 10-year term and are governed by KalVista's Amended and Restated 2021 Equity Inducement Plan, granted under Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) ha annunciato nuove concessioni di incentivazione per i dipendenti assunti di recente. Il 2 gennaio 2025, nove nuovi dipendenti hanno ricevuto opzioni per acquistare un totale di 61.000 azioni ordinarie di KalVista. Inoltre, il 6 gennaio 2025, un nuovo dipendente ha ricevuto opzioni per acquistare 50.000 azioni.
Il prezzo di esercizio delle opzioni corrisponde al prezzo di chiusura delle azioni di KalVista nelle rispettive date di concessione. Il programma di vesting prevede un 25% dopo un anno, con le rimanenti porzioni che maturano mensilmente per tre anni, a condizione che il rapporto di lavoro continui. Tutte le opzioni hanno un periodo di validità di 10 anni e sono regolate dal Piano di Incentivazione Azionaria Emendato e Riformulato del 2021 di KalVista, concesso ai sensi della Regola di Quotazione Nasdaq 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) ha anunciado nuevas concesiones de incentivos para empleados recién contratados. El 2 de enero de 2025, se otorgaron opciones a nueve nuevos empleados para comprar un total de 61,000 acciones ordinarias de KalVista. Además, el 6 de enero de 2025, un nuevo empleado recibió opciones para adquirir 50,000 acciones.
El precio de ejercicio de las opciones es igual al precio de cierre de las acciones de KalVista en las fechas de concesión correspondientes. El calendario de consolidación incluye un 25% después de un año, con las porciones restantes consolidándose mensualmente durante tres años, condicionado a la continuidad del empleo. Todas las opciones tienen un plazo de 10 años y están regidas por el Plan de Incentivos de Capital enmendado y restablecido de 2021 de KalVista, otorgado bajo la Regla de Cotización Nasdaq 5635(c)(4).
칼비스타 제약(KalVista Pharmaceuticals, NASDAQ: KALV)은 최근에 채용된 직원들을 위한 새로운 유인 보상을 발표했습니다. 2025년 1월 2일, 아홉 명의 새로운 직원이 칼비스타 보통주 61,000주를 구매할 수 있는 옵션을 부여받았습니다. 또한, 2025년 1월 6일, 한 명의 새로운 직원은 50,000주를 구매할 수 있는 옵션을 받았습니다.
옵션의 행사가격은 각 부여 날짜의 칼비스타 주식 종가와 동일합니다. 권리 부여 일정은 1년 후 25%가 부여되며, 나머지 부분은 3년에 걸쳐 매월 부여되며, 지속적인 고용을 조건으로 합니다. 모든 옵션은 10년의 유효 기간을 가지고 있으며, NASDAQ 상장 규칙 5635(c)(4)에 따라 부여된 칼비스타의 개정 및 재작성된 2021년 자본 유인 계획에 의해 관리됩니다.
KalVista Pharmaceuticals (NASDAQ: KALV) a annoncé de nouvelles attributions d'incitation pour les employés récemment embauchés. Le 2 janvier 2025, neuf nouveaux employés se sont vu attribuer des options pour acheter un total de 61 000 actions ordinaires de KalVista. De plus, le 6 janvier 2025, un nouvel employé a reçu des options pour acheter 50 000 actions.
Le prix d'exercice des options correspond au prix de clôture des actions KalVista aux dates de concession respectives. Le calendrier d'acquisition comprend 25 % après un an, les portions restantes s'acquérant mensuellement sur trois ans, sous réserve de la continuité de l'emploi. Toutes les options ont une durée de 10 ans et sont régies par le Plan d'Attribution d'Actions Aménagé et Révisé de 2021 de KalVista, attribué conformément à la Règle de Cotation Nasdaq 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) hat neue Anreizgewährungen für kürzlich eingestellte Mitarbeiter angekündigt. Am 2. Januar 2025 wurden neun neuen Mitarbeitern Optionen zum Erwerb von insgesamt 61.000 Aktien von KalVista gewährt. Zudem erhielt am 6. Januar 2025 ein neuer Mitarbeiter Optionen zum Kauf von 50.000 Aktien.
Der Ausübungspreis der Optionen entspricht dem Schlusskurs der KalVista-Aktien an den jeweiligen Zuteilungstagen. Der Vesting-Zeitplan umfasst 25% nach einem Jahr, wobei die verbleibenden Teile monatlich über einen Zeitraum von drei Jahren vested werden, vorausgesetzt, das Arbeitsverhältnis besteht fort. Alle Optionen haben eine Laufzeit von 10 Jahren und unterliegen dem geänderten und erneuerten Eigenkapitalanreizplan von KalVista aus dem Jahr 2021, der gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt wurde.
- Stock option grants help attract and retain key talent
- Structured vesting schedule promotes long-term employee retention
- Potential future dilution of existing shareholders from 111,000 new stock options
Additionally, on January 6, 2025, the Committee granted one newly-hired employee inducement options to purchase an aggregate of 50,000 shares of KalVista common stock as an inducement material to such employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date.
One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the newly-hired employees’ continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Amended and Restated 2021 Equity Inducement Plan and a stock option agreement covering the grant.
The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet needs. Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date of June 17, 2025. We have also completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other countries.
For more information, please visit www.kalvista.com or follow us on social media at @KalVista and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108787745/en/
KalVista Pharmaceuticals, Inc.
Media:
Jenn Snyder
Vice President, Corporate Affairs
(857) 356-0479
jennifer.snyder@kalvista.com
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
FAQ
How many shares of KALV stock options were granted in January 2025?
What is the vesting schedule for KALV's January 2025 inducement grants?
What is the exercise price for KALV's January 2025 inducement grants?
How long is the term of KALV's January 2025 inducement stock options?
